These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 16573802)

  • 1. Aspirin: the miracle drug?
    Thota PN
    Clin Transl Gastroenterol; 2018 May; 9(5):153. PubMed ID: 29720629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking.
    Nguyen T; Tang Z; Younes M; Alsarraj A; Ramsey D; Fitzgerald S; Kramer JR; El-Serag HB
    Dig Dis Sci; 2015 Jan; 60(1):65-73. PubMed ID: 25185658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett's esophagus.
    Taddei A; Fabbroni V; Pini A; Lucarini L; Ringressi MN; Fantappiè O; Bani D; Messerini L; Masini E; Bechi P
    Dig Dis Sci; 2014 May; 59(5):949-57. PubMed ID: 24357184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats.
    Esquivias P; Morandeira A; Escartín A; Cebrián C; Santander S; Esteva F; García-González MA; Ortego J; Lanas A; Piazuelo E
    World J Gastroenterol; 2012 Sep; 18(35):4866-74. PubMed ID: 23002358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barrett esophagus: perspectives on its diagnosis and management in asian populations.
    Amano Y; Kinoshita Y
    Gastroenterol Hepatol (N Y); 2008 Jan; 4(1):45-53. PubMed ID: 22798736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
    Falk GW; Buttar NS; Foster NR; Ziegler KL; Demars CJ; Romero Y; Marcon NE; Schnell T; Corley DA; Sharma P; Cruz-Correa MR; Hur C; Fleischer DE; Chak A; Devault KR; Weinberg DS; Della'Zanna G; Richmond E; Smyrk TC; Mandrekar SJ; Limburg PJ;
    Gastroenterology; 2012 Oct; 143(4):917-26.e1. PubMed ID: 22796132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus.
    Fleischer DE; Odze R; Overholt BF; Carroll J; Chang KJ; Das A; Goldblum J; Miller D; Lightdale CJ; Peters J; Rothstein R; Sharma VK; Smith D; Velanovich V; Wolfsen H; Triadafilopoulos G
    Dig Dis Sci; 2010 Jul; 55(7):1918-31. PubMed ID: 20405211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's esophagus: where do we stand?
    Al Madi MA
    Saudi J Gastroenterol; 2009 Jan; 15(1):2-10. PubMed ID: 19568547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention in Barrett's esophagus.
    Ilyas S; DeMars CJ; Buttar NS
    J Gastrointest Cancer; 2007; 38(1):1-9. PubMed ID: 19065715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic screening and surveillance for Barrett's esophagus--clinical implications.
    Barr H; Kendall C; Bazant-Hegemark F; Moayyedi P; Shetty G; Stone N
    MedGenMed; 2006 Jun; 8(2):88. PubMed ID: 16926827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year.
    de Bortoli N; Martinucci I; Piaggi P; Maltinti S; Bianchi G; Ciancia E; Gambaccini D; Lenzi F; Costa F; Leonardi G; Ricchiuti A; Mumolo MG; Bellini M; Blandizzi C; Marchi S
    Aliment Pharmacol Ther; 2011 May; 33(9):1019-27. PubMed ID: 21385192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
    Spechler SJ; Barker PN; Silberg DG
    Aliment Pharmacol Ther; 2009 Jul; 30(2):138-45. PubMed ID: 19438416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical treatment of Barrett's esophagus].
    Kinoshita Y; Yuki T
    Nihon Rinsho; 2005 Aug; 63(8):1449-53. PubMed ID: 16101238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: is stringent control of gastric pH useful and practical in GERD?
    Kahrilas PJ
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus.
    Triadafilopoulos G; Kaur B; Sood S; Traxler B; Levine D; Weston A
    Aliment Pharmacol Ther; 2006 Apr; 23(7):997-1005. PubMed ID: 16573802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus.
    Kaur BS; Khamnehei N; Iravani M; Namburu SS; Lin O; Triadafilopoulos G
    Gastroenterology; 2002 Jul; 123(1):60-7. PubMed ID: 12105834
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.